Your browser doesn't support javascript.
loading
The use of a potential novel tool in virtual crossmatching for platelet transfusion in platelet refractoriness.
Bub, C B; Gonçalez, A C; Barjas-Castro, M L; Sousa, L C D M; do Monte, S J H; Castro, V.
Afiliação
  • Bub CB; Hematology and Hemotherapy Center, University of Campinas - UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS), Campinas, Brazil.
  • Gonçalez AC; Hematology and Hemotherapy Center, University of Campinas - UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS), Campinas, Brazil.
  • Barjas-Castro ML; Hematology and Hemotherapy Center, University of Campinas - UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS), Campinas, Brazil.
  • Sousa LC; Immunogenetics and Molecular Biology Laboratory, Federal University of Piauí, Teresina, Brazil.
  • do Monte SJ; Immunogenetics and Molecular Biology Laboratory, Federal University of Piauí, Teresina, Brazil.
  • Castro V; Hematology and Hemotherapy Center, University of Campinas - UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS), Campinas, Brazil.
Vox Sang ; 110(1): 70-8, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26274830
BACKGROUND AND OBJECTIVES: Transfusion support for immune-mediated platelet refractoriness (PR) is clinically challenging, technically laborious and costly. The development of 'EpHLA/EpVix software' has been used successfully to select kidney donors. Here, we sought to evaluate this new software as a tool for platelet virtual crossmatch (VxM). MATERIALS AND METHODS: This is a prospective study from 2007 to 2014 of PR patients in a tertiary hospital. Platelet components selected by HLAMatchmaker program were crossmatched by EpHLA/EpVix, anti-human globulin complement-dependent lymphocytotoxicity test (AHG-CDC), flow cytometry platelet crossmatch (FCxM) and then compared. Effectiveness of platelet components transfused was evaluated by CCI. RESULTS: Ninety-seven crossmatched platelet transfusions for 27 patients were enrolled. Partial matches were analysed for 75 transfusions by the 3 methods, and 22% showed discrepant results among the assays. After further analysis, data showed that all divergent cases could be explained by HPA alloimmunization, prozone effect (FCxM), low sensitivity of AHG-CDC and possible interference in FCxM/AHG-CDC assays. Notably, sensitivity and specificity of VxM analysis was excellent (100%). Satisfactory CCI counts were obtained for the majority (22/30) of the transfusions. CONCLUSION: The new EpHLA/EpVix method showed to be effective, feasible and fast for VxM at no cost and able to minimize labour on donor identification. However, platelet crossmatching may be a necessary step because EpHLA/EpVix does not formally exclude HPA alloimmunization.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Software / Tipagem e Reações Cruzadas Sanguíneas / Teste de Histocompatibilidade / Transfusão de Plaquetas / Seleção do Doador Tipo de estudo: Diagnostic_studies / Evaluation_studies / Observational_studies Limite: Adolescent / Adult / Aged / Child, preschool / Female / Humans / Infant / Middle aged Idioma: En Revista: Vox Sang Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Software / Tipagem e Reações Cruzadas Sanguíneas / Teste de Histocompatibilidade / Transfusão de Plaquetas / Seleção do Doador Tipo de estudo: Diagnostic_studies / Evaluation_studies / Observational_studies Limite: Adolescent / Adult / Aged / Child, preschool / Female / Humans / Infant / Middle aged Idioma: En Revista: Vox Sang Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido